ä»ãã大è¦æ¨¡æ¥ç¨®ã»ã³ã¿ã¼ã¸è¡ããããµããããã§ãããããªãããªï½ã¨ç¾¨ãã§ãã¾ãã æ±äº¬ã«ä½ãæ¯ã1åç®ã®ã¯ã¯ãã³æ¥ç¨®ãåãã¾ããã 2åç®ã¯7æã®åãã«ããããã§ã7æã®ä¸æ¬ã«ã¯æä½ãã§ããã§ãããã ä¸æ¹ç§ãæ®ããæ¾æ¬å¸ã§ã¯ãç¾å¨70æ³ä»¥ä¸ã®äººã対象ã«æ¥ç¨®ãè¡ããã¦ãã¾ããç§ã®å¹´é½¢ã§åºç¤ç¾æ£ãªãã ã¨8æã«å ¥ã£ã¦ããã«ãªãããã§ããã¾ã ã¾ã å ã ãªãã ç¾å¨ã¢ã¡ãªã«ã§ã¯ãã©ããã©ãããç¶æ ã§äºç´ãªãã¦ããã¡ãã¡ã§ãã³ãã³æã¦ããããã§ããã大éæã ããã©ãããæã¯ããï¼ã£ã¦ããã¢ã¡ãªã«ã®ããããã¨ããã好ãã§ããããã«å¼ãæãæ¥æ¬ã¯ã»ã»ã» ç§ãæ©ãã¯ã¯ãã³æã£ã¦å®å¿ãããã§ãã
ãããªå ±åããã©ã³ã¹é©å½è¨å¿µæ¥ã®14æ¥ãã¤ã³ãç±æ¥ã®æ°åã³ããã¦ã¤ã«ã¹å¤ç°æ ªããã«ã¿æ ªãæµè¡ãé£ãæ¢ããããã«ã¯ã¯ãã³æ¥ç¨®ã®ä¿é²ãå³ãæ¿åºã®å¼·ç¡¬çã«æè°ããèªç±ãã訴ãããã¢ãããªãåé¨ãªã¨ã³ãªã©å½å ã®é½å¸ã§è¡ããããå°å ã¡ãã£ã¢ã«ããã¨è¨1ä¸9å人以ä¸ãåå ããã ãã¯ãã³å¤§çµ±é ã¯12æ¥ãå»çé¢ä¿è ã®ã¯ã¯ãã³æ¥ç¨®ã義ååããä¸è¬å¸æ°ãæ¥ç¨®å®äºãé°æ§ã®è¨¼æããªããã°8æãã飲é£åºã大è¦æ¨¡åæ¥æ½è¨ãç é¢ãªã©ãå©ç¨ã§ããªãããæªç½®ãçºè¡¨ãããããªã§ã¯14æ¥ã2å人以ä¸ããã¢è¡é²ããç¬è£ã«å対ãããã¨è¨´ãããæç³ãªã©ããããè¦å®éã¯å¬æ¶ã¬ã¹ã§å¿ããã
大貫åðºð¦ð¯ðµÐ УкÑаÑÐ½Ð¾Ñ @ohnuki_tsuyoshi ä¸é¨ã®äººããæ°åã³ããã¯ã¯ãã³ã¯æ²»é¨ãçµãã£ã¦ããªããã¨è¨ã£ã¦ã¦ãå®éã«ã¢ã¡ãªã«ã®æ¿åºãµã¤ãã¨ãè¦ãã¨æ²»é¨æéã2023å¹´ã¾ã§ã¨ãã«è¦ããåé¡ãããããç解ã§ããã 販売ã¾ã§ã«å¿ è¦ãªãæ²»é¨ãã¨ã販売å¾ã«è¿½è·¡èª¿æ»ãããå¸è²©å¾è¨åºè©¦é¨ãããã©ã¡ããè±èªã§ã¯ãclinical trialããªãã ã 2021-07-13 22:31:36 大貫åðºð¦ð¯ðµÐ УкÑаÑÐ½Ð¾Ñ @ohnuki_tsuyoshi æ¢ã«çµãã£ã¦ãclinical trial Phase3ã¾ã§ãæ¥æ¬ã§è¨ãã¨ããã®æ²»é¨ãã§ã¼ãº3ã¾ã§ã§ãç¾å¨é²è¡ä¸ã®clinical trial Phase4ã¯æ¥æ¬ã§ã¯å¸è²©å¾è¨åºè©¦é¨ã¨å¼ã°ãããã®ãæ²»é¨ã§ã¯è¦ã¤ããããªãã£ãç¨ãªå¯ä½ç¨ãªã©ããªãã調æ»ãããã®ã 2021-07-13 22:34:19
æ°åã³ããã¦ã¤ã«ã¹å¯¾çã«ã¤ãã¦å©è¨ããåçå´åçã®å°é家ä¼åããæ±äº¬é½ã«4åç®ã®ç·æ¥äºæ 宣è¨ãåºããã¦ããåãã¦éããã¾ããã å°é家ä¼åã§ã¯ãç¾å¨ã®ææç¶æ³ã«ã¤ãã¦ãæ±äº¬é½ãä¸å¿ã¨ããé¦é½åã®æææ¡å¤§ãé¡èã§ãå¨è¾ºãå ¨å½ã¸ã®å½±é¿ãæ¸å¿µããããã¨è©ä¾¡ãã¾ããã ã¾ãã¤ã³ãã§è¦ã¤ãã£ãå¤ç°ããæ°åã³ããã¦ã¤ã«ã¹ããã«ã¿æ ªãã«ã¤ãã¦ãåçå´åçãªã©ãææè ã®ä¸é¨ã®æ¤ä½ãéºä¼å解æããçµæã12æ¥ã¾ã§ã®1é±éã«ç¢ºèªãããã®ã¯åã®é±ã®ããã1.7åã«æ¥å¢ãããã¨ããããã¾ããã é¦é½åã®ææè æ° å ¨å½ã®ç´3åã®2 å°åå¥ã«ã¿ãã¨ãæ±äº¬é½ã§ã¯ãæ°è¦ææè æ°ã®å¢å ãç¶ãã20代ãã40代ãå¤ããå ããå ¥é¢è æ°ã®å¢å å¾åãç¶ç¶ãã¦ããã¨ãã¦ãã¾ãã æ±äº¬é½ã®éçè æ°ã¯40代ã50代ã§ã¯ååãææã®ç¬¬4æ³¢ã®ãã¼ã¯æã¨åæ°´æºã«ãªã£ã¦ãã¦ãç·æ¥äºæ 宣è¨ã®å¹æãåºãã¾ã§å°ãªãã¨ã2é±éç¨åº¦ããããã¨ãè¦è¾¼ã¾ãã
æããããæ票ã«è¡ããââããµã¤ã¼ãªã¤ã®å åï¼ã»ãã®ï¼ä¸æ社é·ã¯14æ¥ã®æ±ºç®ä¼è¦ã§ãã³ããç¦ã§è¦ãã飲é£æ¥çã®æåãæ¿çã«åæ ãããªãçç±ã¨ãã¦é¢ä¿è ã®ãæ票çã®ä½ãããæãããä»ç§ã¾ã§ã«ããç·é¸æâ¦
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}